BMRN Quote, Financials, Valuation and Earnings

Inozyme Pharma has a net margin of 24.92% compared to Biomarin Pharmaceutical's net margin of --. Biomarin Pharmaceutical's return on equity of 9.62% beat Inozyme Pharma's return on equity of --.

Biomarin Pharmaceutical has a consensus price target of $95.91, signalling upside risk potential of 70.54%. On the other hand Inozyme Pharma has an analysts' consensus of $6.83 which suggests that it could grow by 0.76%. Given that Biomarin Pharmaceutical has higher upside potential than Inozyme Pharma, analysts believe Biomarin Pharmaceutical is more attractive than Inozyme Pharma.

Biomarin Pharmaceutical has a beta of 0.190, which suggesting that the stock is 80.953% less volatile than S&P 500. In comparison Inozyme Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inozyme Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Inozyme Pharma pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.1M, which are larger than Inozyme Pharma quarterly revenues of --. Biomarin Pharmaceutical's net income of $185.7M is higher than Inozyme Pharma's net income of -$28M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 20.91x while Inozyme Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.77x versus -- for Inozyme Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 24.92% compared to Biomarin Pharmaceutical's net margin of -907.48%. Biomarin Pharmaceutical's return on equity of 9.62% beat Moderna's return on equity of -29.23%.

Biomarin Pharmaceutical has a consensus price target of $95.91, signalling upside risk potential of 70.54%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 83.04%. Given that Moderna has higher upside potential than Biomarin Pharmaceutical, analysts believe Moderna is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.190, which suggesting that the stock is 80.953% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.1M, which are larger than Moderna quarterly revenues of $107M. Biomarin Pharmaceutical's net income of $185.7M is higher than Moderna's net income of -$971M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 20.91x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.77x versus 3.22x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 24.92% compared to Biomarin Pharmaceutical's net margin of -60.08%. Biomarin Pharmaceutical's return on equity of 9.62% beat Sarepta Therapeutics's return on equity of -20.94%.

Biomarin Pharmaceutical has a consensus price target of $95.91, signalling upside risk potential of 70.54%. On the other hand Sarepta Therapeutics has an analysts' consensus of $60.25 which suggests that it could grow by 226.81%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.190, which suggesting that the stock is 80.953% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.1M, which are larger than Sarepta Therapeutics quarterly revenues of $744.9M. Biomarin Pharmaceutical's net income of $185.7M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 20.91x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.77x versus 1.04x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 24.92% compared to Biomarin Pharmaceutical's net margin of 23.33%. Biomarin Pharmaceutical's return on equity of 9.62% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Biomarin Pharmaceutical has a consensus price target of $95.91, signalling upside risk potential of 70.54%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 10.91%. Given that Biomarin Pharmaceutical has higher upside potential than Vertex Pharmaceuticals, analysts believe Biomarin Pharmaceutical is more attractive than Vertex Pharmaceuticals.

Biomarin Pharmaceutical has a beta of 0.190, which suggesting that the stock is 80.953% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.1M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Biomarin Pharmaceutical's net income of $185.7M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 20.91x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.77x versus 10.52x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.